Gary T Ferguson

List of Publications by Year
in descending order

55 papers	7,759 citations	257450 24 h-index	155660 55 g-index
55 all docs	55 docs citations	55 times ranked	5145 citing authors

#	Article	IF	Citations
1	Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions. PharmacoEconomics - Open, 2021, 5, 3-11.	1.8	27
2	Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS. International Journal of COPD, 2021, Volume 16, 179-189.	2.3	9
3	Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. Advances in Therapy, 2021, 38, 3089-3112.	2.9	15
4	TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow. International Journal of COPD, 2021, Volume 16, 2455-2465.	2.3	4
5	Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. Respiratory Medicine, 2021, 185, 106509.	2.9	12
6	Unreported and Overlooked: A Post Hoc Analysis of COPD Symptom-Related Attacks from the RISE Study . International Journal of COPD, 2020, Volume 15, 3123-3134.	2.3	2
7	Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADOÂ® studies. Npj Primary Care Respiratory Medicine, 2020, 30, 53.	2.6	2
8	Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respiratory Research, 2020, 21, 131.	3.6	25
9	Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADOÂ® and OTEMTOÂ® Studies. Advances in Therapy, 2020, 37, 3485-3499.	2.9	7
10	Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Î²2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. Advances in Therapy, 2020, 37, 2956-2975.	2.9	15
11	Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study. Respiratory Research, 2019, 20, 167.	3.6	18
12	A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD. Advances in Therapy, 2019, 36, 2434-2449.	2.9	22
13	Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial Results . Journal of Asthma and Allergy, 2019, Volume 12, 363-373.	3.4	14
14	A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6â€Î¼g and 160/18/9.6â€Î¼g using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. Respiratory Medicine, 2019, 158, 59-66.	2.9	27
15	Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD . International Journal of COPD, 2019, Volume 14, 2993-3002.	2.3	12
16	Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study . International Journal of COPD, 2019, Volume 14, 2979-2991.	2.3	12
17	Effects of baseline symptom burden on treatment response in COPD. International Journal of COPD, 2019, Volume 14, 181-194.	2.3	8
18	Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2019, 32, 24-33.	1.4	5

#	Article	IF	Citations
19	Effect of tiotropium on spontaneous expiratory flowâ€“volume curves during exercise in GOLD 1-2 COPD. Respiratory Physiology and Neurobiology, 2018, 251, 8-15.	1.6	8
20	Î²-Blockers in COPD. Chest, 2018, 153, 1315-1325.	0.8	29
21	Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology. Pulmonary Pharmacology and Therapeutics, 2018, 49, 67-74.	2.6	6
22	Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases. Respiratory Medicine, 2018, 134, 16-23.	2.9	26
23	In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, 31, 162-169.	1.4	20
24	Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 747-758.	10.7	254
25	Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. Respiratory Medicine, 2018, 143, 67-73.	2.9	16
26	Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. European Respiratory Journal, 2018, 52, 1801334.	6.7	16
27	An overview of glycopyrrolate/eFlowÂ® CS in COPD. Expert Review of Respiratory Medicine, 2018, 12, 447-459.	2.5	5
28	Clinical implications of the tiotropium/olodaterol inhaler for patients with chronic obstructive pulmonary disease. Postgraduate Medicine, 2018, 130, 515-522.	2.0	2
29	Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma. Journal of Asthma and Allergy, 2018, Volume 11, 63-72.	3.4	22
30	Health-Related Quality of Life Improvements in Moderate to Very Severe Chronic Obstructive Pulmonary Disease Patients on Nebulized Glycopyrrolate: Evidence from the GOLDEN Studies. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2018, 5, 193-207.	0.7	3
31	Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. Npj Primary Care Respiratory Medicine, 2017, 27, 7.	2.6	24
32	Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. Chest, 2017, 151, 340-357.	0.8	91
33	Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2017, 5, 568-576.	10.7	99
34	Long-term safety of glycopyrrolate/eFlowÂ® CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study. Respiratory Medicine, 2017, 132, 251-260.	2.9	19
35	Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the) Tj ETQq1 1 0.784314 rgBT /Overlock	2.9	30
36	Efficacy and safety of glycopyrrolate/eFlowÂ® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respiratory Medicine, 2017, 132, 238-250.	2.9	36

#	Article	IF	Citations
37	Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age . International Journal of COPD, 2016, Volume 11, 2701-2710.	2.3	17
38	Effects of tiotropiumâ€‰+â€‰olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTOÂ® studies. Respiratory Research, 2016, 17, 73.	3.6	37
39	Benralizumab, an anti-interleukin-5 receptor Î± monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, The, 2016, 388, 2128-2141.	13.7	1,070
40	Tiotropium and olodaterol fixed-dose combination‹i›versus‹/i›mono-components in COPD (GOLD) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	6.7	294
41	One-Year Safety of Olodaterol Once Daily via RespimatÂ® in Patients with GOLD 2â€“4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 484-493.	1.6	29
42	TiotropiumÂ+Âolodaterol shows clinically meaningful improvements in quality of life. Respiratory Medicine, 2015, 109, 1312-1319.	2.9	144
43	Efficacy of TiotropiumÂ+ÂOlodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis. Advances in Therapy, 2015, 32, 523-536.	2.9	44
44	Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. International Journal of COPD, 2014, 9, 629.	2.3	68
45	Dual bronchodilation with QVA149‹i›versus‹/i›single bronchodilator therapy: the SHINE study. European Respiratory Journal, 2013, 42, 1484-1494.	6.7	358
46	COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study. International Journal of COPD, 2013, 8, 139.	2.3	20
47	Maintenance pharmacotherapy of mild and moderate COPD: What is the Evidence?. Respiratory Medicine, 2011, 105, 1268-1274.	2.9	14
48	Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. International Journal of COPD, 2011, 6, 573.	2.3	40
49	Prevalence and Progression of Osteoporosis in Patients With COPD. Chest, 2009, 136, 1456-1465.	0.8	240
50	Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009, 6, 320-329.	1.6	154
51	Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research, 2009, 10, 59.	3.6	287
52	Effect of fluticasone propionate/salmeterol (250/50Î¼g) or salmeterol (50Î¼g) on COPD exacerbations. Respiratory Medicine, 2008, 102, 1099-1108.	2.9	211
53	Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 332-338.	5.6	692
54	Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2007, 356, 775-789.	27.0	2,963

#	Article	IF	Citations
55	Why Does the Lung Hyperinflate?. Proceedings of the American Thoracic Society, 2006, 3, 176-179.	3.5	125